$HALO News

This Medical Technology Stock Claws Back To A Buy Zone

Halozyme: Unique Business Model -- Adds A Powerful Leavening Element To Any Biotech Portfolio

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine?

Halozyme and Incyte sign licence agreement for INCA033989 formulations

Halozyme and Incyte sign licence agreement for INCA033989 formulations

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $95 Price Target

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

2 Reasons to Like HALO and 1 to Stay Skeptical

Halozyme Appoints David Ramsay as President Drug Delivery

Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

Halozyme Sees Little Royalty Impact From Medicare Drug Pricing Rule, Says CMS Proposal Should Not Hurt ENHANZE Partnerships

How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E

Implied Volatility Surging for Halozyme Therapeutics Stock Options

Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Halozyme Therapeutics: Royalty King